$HAE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HAEMONETICS CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HAEMONETICS CORP. Get notifications about new insider transactions in HAEMONETICS CORP for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 16 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.09 | 400 | 21,636 | 26,423 | 26.8 K to 26.4 K (-1.49 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.07 | 200 | 10,814 | 26,823 | 27 K to 26.8 K (-0.74 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 54.06 | 290 | 15,677 | 27,023 | 27.3 K to 27 K (-1.06 %) |
Nov 14 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 45.45 | 6,573 | 298,743 | 27,313 | 20.7 K to 27.3 K (+31.69 %) |
Oct 19 2017 | HAE | HAEMONETICS CORP | ABERNATHY ROBERT E | Director | Grant | A | 45.30 | 2,909 | 131,763 | 2,909 | 0 to 2.9 K |
Aug 15 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Option Exercise | M | 34.41 | 7,118 | 244,895 | 0 | |
Aug 15 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Option Exercise | M | 32.96 | 16,968 | 559,265 | 0 | |
Aug 15 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Sell | S | 42.10 | 7,118 | 299,701 | 26,911 | 34 K to 26.9 K (-20.92 %) |
Aug 15 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Buy | M | 34.41 | 7,118 | 244,895 | 34,029 | 26.9 K to 34 K (+26.45 %) |
Aug 15 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Sell | S | 42.02 | 16,968 | 712,995 | 26,911 | 43.9 K to 26.9 K (-38.67 %) |
Aug 15 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Buy | M | 32.96 | 16,968 | 559,265 | 43,879 | 26.9 K to 43.9 K (+63.05 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | BURZIK CATHERINE M | Director | Grant | A | 39.27 | 4,329 | 170,000 | 8,599 | 4.3 K to 8.6 K (+101.38 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | Dockendorff Charles J | Director | Grant | A | 39.27 | 4,329 | 170,000 | 17,184 | 12.9 K to 17.2 K (+33.68 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Grant | A | 39.27 | 4,329 | 170,000 | 20,740 | 16.4 K to 20.7 K (+26.38 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Grant | A | 39.27 | 4,329 | 170,000 | 54,017 | 49.7 K to 54 K (+8.71 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | GRANADILLO PEDRO P | Director | Grant | A | 39.27 | 4,329 | 170,000 | 31,663 | 27.3 K to 31.7 K (+15.84 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Grant | A | 39.27 | 4,329 | 170,000 | 26,763 | 22.4 K to 26.8 K (+19.30 %) |
Jul 31 2017 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Grant | A | 39.27 | 4,329 | 170,000 | 26,911 | 22.6 K to 26.9 K (+19.17 %) |
Jun 08 2017 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 41.64 | 104,516 | 4,352,046 | 104,516 | |
Jun 08 2017 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Grant | A | 41.64 | 25,516 | 1,062,486 | 131,383 | 105.9 K to 131.4 K (+24.10 %) |
Jun 08 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Option Exercise | A | 41.64 | 22,870 | 952,307 | 22,870 | |
Jun 08 2017 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Grant | A | 41.64 | 5,583 | 232,476 | 15,996 | 10.4 K to 16 K (+53.62 %) |
Jun 08 2017 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Option Exercise | A | 41.64 | 24,592 | 1,024,011 | 24,592 | |
Jun 08 2017 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Grant | A | 41.64 | 6,003 | 249,965 | 10,882 | 4.9 K to 10.9 K (+123.04 %) |
Jun 08 2017 | HAE | HAEMONETICS CORP | Ryding Neil 122-62-507 | EVP, Global Manufac ... | Option Exercise | A | 41.64 | 9,836 | 409,571 | 9,836 | |
Jun 08 2017 | HAE | HAEMONETICS CORP | Ryding Neil 122-62-507 | EVP, Global Manufac ... | Grant | A | 41.64 | 2,401 | 99,978 | 19,676 | 17.3 K to 19.7 K (+13.90 %) |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Option Exercise | M | 36.37 | 8,196 | 298,089 | 0 | |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 40.32 | 8,196 | 330,427 | 17,807 | 26 K to 17.8 K (-31.52 %) |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Buy | M | 36.37 | 8,196 | 298,089 | 26,003 | 17.8 K to 26 K (+46.03 %) |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Option Exercise | M | 35.50 | 10,353 | 367,557 | 0 | |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Option Exercise | M | 34.41 | 7,118 | 244,895 | 0 | |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 40.34 | 10,353 | 417,602 | 17,807 | 28.2 K to 17.8 K (-36.76 %) |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Buy | M | 30.50 | 10,353 | 315,792 | 28,160 | 17.8 K to 28.2 K (+58.14 %) |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 40.31 | 7,118 | 286,917 | 17,807 | 24.9 K to 17.8 K (-28.56 %) |
May 24 2017 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Buy | M | 34.41 | 7,118 | 244,895 | 24,925 | 17.8 K to 24.9 K (+39.97 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Option Exercise | M | 27.24 | 8,580 | 233,719 | 0 | |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.56 | 307 | 12,759 | 22,434 | 22.7 K to 22.4 K (-1.35 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.55 | 400 | 16,620 | 22,741 | 23.1 K to 22.7 K (-1.73 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.55 | 100 | 4,155 | 23,141 | 23.2 K to 23.1 K (-0.43 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.54 | 273 | 11,340 | 23,241 | 23.5 K to 23.2 K (-1.16 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.53 | 129 | 5,357 | 23,514 | 23.6 K to 23.5 K (-0.55 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.52 | 818 | 33,963 | 23,643 | 24.5 K to 23.6 K (-3.34 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.51 | 276 | 11,455 | 24,461 | 24.7 K to 24.5 K (-1.12 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.50 | 453 | 18,800 | 24,737 | 25.2 K to 24.7 K (-1.80 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.50 | 100 | 4,150 | 25,190 | 25.3 K to 25.2 K (-0.40 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.49 | 100 | 4,149 | 25,290 | 25.4 K to 25.3 K (-0.39 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.49 | 300 | 12,446 | 25,390 | 25.7 K to 25.4 K (-1.17 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.48 | 1,900 | 78,812 | 25,690 | 27.6 K to 25.7 K (-6.89 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.48 | 300 | 12,443 | 27,590 | 27.9 K to 27.6 K (-1.08 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.47 | 1,771 | 73,443 | 27,890 | 29.7 K to 27.9 K (-5.97 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.47 | 300 | 12,440 | 29,661 | 30 K to 29.7 K (-1.00 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.46 | 500 | 20,730 | 29,961 | 30.5 K to 30 K (-1.64 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.46 | 100 | 4,146 | 30,461 | 30.6 K to 30.5 K (-0.33 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.45 | 53 | 2,197 | 30,561 | 30.6 K to 30.6 K (-0.17 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.45 | 200 | 8,290 | 30,614 | 30.8 K to 30.6 K (-0.65 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.45 | 100 | 4,145 | 30,814 | 30.9 K to 30.8 K (-0.32 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Sell | S | 41.44 | 100 | 4,144 | 30,914 | 31 K to 30.9 K (-0.32 %) |
May 17 2017 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Buy | M | 27.24 | 8,580 | 233,719 | 31,014 | 22.4 K to 31 K (+38.25 %) |
May 15 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 36.37 | 8,196 | 298,089 | 0 | |
May 15 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 34.41 | 7,118 | 244,895 | 0 | |
May 15 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 41.78 | 15,314 | 639,819 | 13,251 | 28.6 K to 13.3 K (-53.61 %) |
May 15 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 36.37 | 8,196 | 298,089 | 31,725 | 23.5 K to 31.7 K (+34.83 %) |
May 15 2017 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 34.41 | 7,118 | 244,895 | 23,529 | 16.4 K to 23.5 K (+43.37 %) |
Apr 27 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 27.24 | 8,580 | 233,719 | 0 | |
Apr 27 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 40.00 | 8,580 | 343,200 | 49,688 | 58.3 K to 49.7 K (-14.73 %) |
Apr 27 2017 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 27.24 | 8,580 | 233,719 | 58,268 | 49.7 K to 58.3 K (+17.27 %) |
Mar 08 2017 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Option Exercise | A | 0.00 | 9,758 | 0 | 19,516 | |
Mar 08 2017 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Option Exercise | A | 38.43 | 19,490 | 749,001 | 19,490 | |
Mar 08 2017 | HAE | HAEMONETICS CORP | Basil Michelle L | EVP and General Cou ... | Grant | A | 38.43 | 4,879 | 187,500 | 4,879 | 0 to 4.9 K |
Dec 14 2016 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Sell | S | 40.30 | 5,683 | 229,025 | 49,688 | 55.4 K to 49.7 K (-10.26 %) |
Oct 27 2016 | HAE | HAEMONETICS CORP | BURZIK CATHERINE M | Director | Grant | A | 34.21 | 4,969 | 169,989 | 4,969 | 0 to 5 K |
Oct 27 2016 | HAE | HAEMONETICS CORP | Jesse Sandra | EVP and Chief Legal ... | Option Exercise | A | 0.00 | 6,577 | 0 | 6,577 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Jesse Sandra | EVP and Chief Legal ... | Option Exercise | A | 34.21 | 14,187 | 485,337 | 14,187 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Jesse Sandra | EVP and Chief Legal ... | Grant | A | 34.21 | 3,288 | 112,482 | 48,166 | 44.9 K to 48.2 K (+7.33 %) |
Oct 27 2016 | HAE | HAEMONETICS CORP | Fusco David | EVP, Global Human R ... | Option Exercise | A | 0.00 | 5,261 | 0 | 5,261 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Fusco David | EVP, Global Human R ... | Option Exercise | A | 34.21 | 11,349 | 388,249 | 11,349 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Fusco David | EVP, Global Human R ... | Grant | A | 34.21 | 2,630 | 89,972 | 16,867 | 14.2 K to 16.9 K (+18.47 %) |
Oct 27 2016 | HAE | HAEMONETICS CORP | Selman Byron | President, Global M ... | Option Exercise | A | 0.00 | 7,673 | 0 | 7,673 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Selman Byron | President, Global M ... | Option Exercise | A | 34.21 | 16,551 | 566,210 | 16,551 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Selman Byron | President, Global M ... | Grant | A | 34.21 | 3,836 | 131,230 | 23,318 | 19.5 K to 23.3 K (+19.69 %) |
Oct 27 2016 | HAE | HAEMONETICS CORP | Ryding Neil 122-62-507 | EVP, Global Manufac ... | Option Exercise | A | 0.00 | 6,577 | 0 | 6,577 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Ryding Neil 122-62-507 | EVP, Global Manufac ... | Option Exercise | A | 34.21 | 14,187 | 485,337 | 14,187 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Ryding Neil 122-62-507 | EVP, Global Manufac ... | Grant | A | 34.21 | 3,288 | 112,482 | 17,275 | 14 K to 17.3 K (+23.51 %) |
Oct 27 2016 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Option Exercise | A | 0.00 | 20,827 | 0 | 20,827 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Option Exercise | A | 34.21 | 44,926 | 1,536,918 | 44,926 | |
Oct 27 2016 | HAE | HAEMONETICS CORP | Burke Willaim P | EVP, Chief Financia ... | Grant | A | 34.21 | 10,413 | 356,229 | 10,413 | 0 to 10.4 K |
Aug 25 2016 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Option Exercise | M | 29.72 | 11,758 | 349,448 | 0 | |
Aug 25 2016 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Buy | M | 29.72 | 11,758 | 349,448 | 66,985 | 55.2 K to 67 K (+21.29 %) |
Aug 25 2016 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Payment of Exercise | F | 30.09 | 11,614 | 349,465 | 55,371 | 67 K to 55.4 K (-17.34 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.22 | 10 | 352 | 17,851 | 17.9 K to 17.9 K (-0.06 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.21 | 300 | 10,563 | 17,861 | 18.2 K to 17.9 K (-1.65 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.21 | 130 | 4,577 | 18,161 | 18.3 K to 18.2 K (-0.71 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.20 | 100 | 3,520 | 18,291 | 18.4 K to 18.3 K (-0.54 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.17 | 110 | 3,869 | 18,391 | 18.5 K to 18.4 K (-0.59 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.17 | 200 | 7,033 | 18,501 | 18.7 K to 18.5 K (-1.07 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.16 | 100 | 3,516 | 18,701 | 18.8 K to 18.7 K (-0.53 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.13 | 2,500 | 87,825 | 18,801 | 21.3 K to 18.8 K (-11.74 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.13 | 200 | 7,025 | 21,301 | 21.5 K to 21.3 K (-0.93 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.12 | 187 | 6,567 | 21,501 | 21.7 K to 21.5 K (-0.86 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.12 | 100 | 3,512 | 21,688 | 21.8 K to 21.7 K (-0.46 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.11 | 100 | 3,511 | 21,788 | 21.9 K to 21.8 K (-0.46 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.11 | 100 | 3,511 | 21,888 | 22 K to 21.9 K (-0.45 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.10 | 100 | 3,510 | 21,988 | 22.1 K to 22 K (-0.45 %) |
Aug 19 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Sell | S | 35.09 | 100 | 3,509 | 22,088 | 22.2 K to 22.1 K (-0.45 %) |
Aug 18 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 35.00 | 57,149 | 1,999,981 | 57,149 | |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 27.24 | 8,580 | 233,719 | 0 | |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Option Exercise | M | 27.24 | 8,580 | 233,719 | 0 | |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.32 | 100 | 3,532 | 22,316 | 22.4 K to 22.3 K (-0.45 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.32 | 100 | 3,532 | 22,316 | 22.4 K to 22.3 K (-0.45 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.33 | 200 | 7,066 | 22,116 | 22.3 K to 22.1 K (-0.90 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.33 | 200 | 7,066 | 22,116 | 22.3 K to 22.1 K (-0.90 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.34 | 300 | 10,602 | 21,816 | 22.1 K to 21.8 K (-1.36 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.34 | 300 | 10,602 | 21,816 | 22.1 K to 21.8 K (-1.36 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.35 | 200 | 7,069 | 21,616 | 21.8 K to 21.6 K (-0.92 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.35 | 200 | 7,069 | 21,616 | 21.8 K to 21.6 K (-0.92 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.35 | 5,305 | 187,532 | 16,311 | 21.6 K to 16.3 K (-24.54 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.35 | 5,305 | 187,532 | 16,311 | 21.6 K to 16.3 K (-24.54 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 27.24 | 8,580 | 233,719 | 24,891 | 16.3 K to 24.9 K (+52.60 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Buy | M | 27.24 | 8,580 | 233,719 | 24,891 | 16.3 K to 24.9 K (+52.60 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.35 | 8,280 | 292,698 | 16,611 | 24.9 K to 16.6 K (-33.27 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.35 | 8,280 | 292,698 | 16,611 | 24.9 K to 16.6 K (-33.27 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.36 | 300 | 10,607 | 16,311 | 16.6 K to 16.3 K (-1.81 %) |
Aug 16 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Sell | S | 35.36 | 300 | 10,607 | 16,311 | 16.6 K to 16.3 K (-1.81 %) |
Aug 08 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Buy | P | 35.00 | 60,000 | 2,099,754 | 105,867 | 45.9 K to 105.9 K (+130.81 %) |
Jul 25 2016 | HAE | HAEMONETICS CORP | FOOTE SUSAN BARTLETT | Director | Grant | A | 29.59 | 5,746 | 169,995 | 22,416 | 16.7 K to 22.4 K (+34.47 %) |
Jul 25 2016 | HAE | HAEMONETICS CORP | KROLL MARK W | Director | Grant | A | 29.59 | 5,746 | 169,995 | 22,478 | 16.7 K to 22.5 K (+34.34 %) |
Jul 25 2016 | HAE | HAEMONETICS CORP | MEELIA RICHARD J | Director | Grant | A | 29.59 | 5,746 | 169,995 | 22,626 | 16.9 K to 22.6 K (+34.04 %) |
Jul 25 2016 | HAE | HAEMONETICS CORP | MERRIMAN RONALD | Director | Grant | A | 29.59 | 5,746 | 169,995 | 22,188 | 16.4 K to 22.2 K (+34.95 %) |
Jul 25 2016 | HAE | HAEMONETICS CORP | GELBMAN RONALD G | Director | Grant | A | 29.59 | 5,746 | 169,995 | 55,271 | 49.5 K to 55.3 K (+11.60 %) |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 0.00 | 65,525 | 0 | 91,735 | |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 0.00 | 65,525 | 0 | 91,735 | |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 0.00 | 26,210 | 0 | 26,210 | |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 0.00 | 26,210 | 0 | 26,210 | |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 28.62 | 196,746 | 5,629,887 | 196,746 | |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Option Exercise | A | 28.62 | 196,746 | 5,629,887 | 196,746 | |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Grant | A | 0.01 | 45,867 | 459 | 45,867 | 0 to 45.9 K |
Jul 01 2016 | HAE | HAEMONETICS CORP | Simon, Christopher | President & CEO | Grant | A | 0.01 | 45,867 | 459 | 45,867 | 0 to 45.9 K |
Jan 19 2016 | HAE | HAEMONETICS CORP | Ryding Neil 122-62-507 | EVP, Global Manufac ... | Grant | A | 0.01 | 9,765 | 98 | 13,987 | 4.2 K to 14 K (+231.29 %) |
Jan 19 2016 | HAE | HAEMONETICS CORP | Fusco David | EVP, Global Human R ... | Grant | A | 0.01 | 8,138 | 81 | 13,553 | 5.4 K to 13.6 K (+150.29 %) |
Jan 19 2016 | HAE | HAEMONETICS CORP | Jesse Sandra | EVP and Chief Legal ... | Grant | A | 0.01 | 9,765 | 98 | 29,861 | 20.1 K to 29.9 K (+48.59 %) |
Jan 19 2016 | HAE | HAEMONETICS CORP | LINDOP CHRISTOPHER J | CFO & EVP Business ... | Grant | A | 0.01 | 11,393 | 114 | 56,743 | 45.4 K to 56.7 K (+25.12 %) |
Jan 19 2016 | HAE | HAEMONETICS CORP | Selman Byron | President, Global M ... | Grant | A | 0.01 | 8,138 | 81 | 20,148 | 12 K to 20.1 K (+67.76 %) |
Oct 28 2015 | HAE | HAEMONETICS CORP | Selman Byron | President, Global M ... | Sell | S | 32.13 | 344 | 11,052 | 12,010 | 12.4 K to 12 K (-2.78 %) |
Oct 28 2015 | HAE | HAEMONETICS CORP | White Jonathan | Chief Science and T ... | Sell | S | 32.13 | 319 | 10,249 | 30,507 | 30.8 K to 30.5 K (-1.03 %) |
Oct 28 2015 | HAE | HAEMONETICS CORP | Jesse Sandra | EVP and Chief Legal ... | Sell | S | 32.13 | 778 | 24,996 | 20,096 | 20.9 K to 20.1 K (-3.73 %) |
Oct 28 2015 | HAE | HAEMONETICS CORP | HANLON SUSAN M | VP Finance | Sell | S | 32.13 | 497 | 15,968 | 20,464 | 21 K to 20.5 K (-2.37 %) |
Oct 28 2015 | HAE | HAEMONETICS CORP | LINDOP CHRISTOPHER J | CFO & EVP Business ... | Sell | S | 32.13 | 436 | 14,008 | 45,350 | 45.8 K to 45.4 K (-0.95 %) |
Oct 27 2015 | HAE | HAEMONETICS CORP | Davies Kent J | Chief Operating Off ... | Sell | S | 31.75 | 278 | 8,826 | 16,891 | 17.2 K to 16.9 K (-1.62 %) |
Oct 27 2015 | HAE | HAEMONETICS CORP | Selman Byron | President, Global M ... | Sell | S | 31.75 | 191 | 6,064 | 11,296 | 11.5 K to 11.3 K (-1.66 %) |
Oct 27 2015 | HAE | HAEMONETICS CORP | Jesse Sandra | EVP and Chief Legal ... | Sell | S | 31.75 | 250 | 7,937 | 18,486 | 18.7 K to 18.5 K (-1.33 %) |